Both IMM and IMU have good potentials. I think what IMU does well recently is investor education. It would be great if IMM can do more on this. Oncology is exciting but can be hard to understand for many investors.
Ann: Ulcerative Colitis Phase II Study of GSK2831781 Discontinued, page-13
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
35.5¢ |
Change
0.060(20.3%) |
Mkt cap ! $515.6M | |||
| Open | High | Low | Value | Volume |
| 36.0¢ | 37.5¢ | 33.5¢ | $6.427M | 18.03M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 50000 | 35.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 36.0¢ | 133736 | 5 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |